Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2026: Is biotech back? Four drugmakers go public, raising $1 billion total
Eikon Therapeutics, Inc.

Organization & Developments: Eikon Therapeutics

Parents

*Eikon Therapeutics is a biopharmaceutical company employing revolutionary technology at the interface of biology, engineering, and chemistry to discover novel treatments for life-threatening diseases.
*Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes that enable real-time, molecular-resolution measurements of protein movement in living cells.
*Pipeline of more than 15 drug candidates for cancer, inflammatory conditions and neurological diseases
2025: Layoffs, shutdowns and billions up in smoke. What's wrong with Bay Area biotech?